The estimated Net Worth of Michael C Donegan is at least $682 Tausend dollars as of 12 April 2023. Mr. Donegan owns over 50,000 units of TherapeuticsMD Inc stock worth over $109,968 and over the last 9 years he sold TXMD stock worth over $0. In addition, he makes $572,084 as Vice President - Finance at TherapeuticsMD Inc.
Sign up
Mr. Donegan TXMD stock SEC Form 4 insiders trading
Michael has made over 6 trades of the TherapeuticsMD Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of TXMD stock worth $88,895 on 12 April 2023.
The largest trade he's ever made was exercising 115,000 units of TherapeuticsMD Inc stock on 30 November 2021 worth over $204,459. On average, Michael trades about 8,599 units every 31 days since 2015. As of 12 April 2023 he still owns at least 61,853 units of TherapeuticsMD Inc stock.
You can see the complete history of Mr. Donegan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Donegan biography
Michael Donegan serves as Vice President - Finance of the Company. since April 2013. He has served as Vice President – Finance of our company since April 2013. Mr. Donegan has a 28-year background in accounting and finance. From August 2012 to April 2013, Mr. Donegan served as an independent consultant exclusively for our company, where he conceptualized, designed and executed our Sarbanes-Oxley 404 compliance program. From August 2007 to August 2012, Mr. Donegan served as an independent consultant designing and implementing Sarbanes-Oxley 404 compliance programs for various non-accelerated filers and executed on pre-designed Sarbanes-Oxley 404 compliance programs for certain large accelerated filers. From January 2005 to August 2007, Mr. Donegan served as an independent consultant exclusively for Tyco International, where he enhanced and executed the Sarbanes-Oxley 404 compliance model with their corporate headquarters group. From November 2001 to December 2004, Mr. Donegan was Manager of Financial Systems at Tyco International at its global headquarters. From 1994 to 2001, Mr. Donegan held various positions in the global consolidation/SEC reporting group at Sensormatic Electronics Corporation culminating with the acquisition of Sensormatic Electronics Corporation by Tyco International in the fall of 2001 when he was the Manager of Financial Systems. Mr. Donegan began his career at Ernst & Young, LLP where he worked in both the audit and tax departments. Mr. Donegan earned his B.S. in Accounting and his Master of Accounting from the University of Florida.
What is the salary of Michael Donegan?
As the Vice President - Finance of TherapeuticsMD Inc, the total compensation of Michael Donegan at TherapeuticsMD Inc is $572,084. There are 6 executives at TherapeuticsMD Inc getting paid more, with John Milligan having the highest compensation of $1,440,640.
How old is Michael Donegan?
Michael Donegan is 52, he's been the Vice President - Finance of TherapeuticsMD Inc since 2013. There are 14 older and 12 younger executives at TherapeuticsMD Inc. The oldest executive at TherapeuticsMD Inc is Tommy Thompson, 78, who is the Independent Chairman of the Board.
What's Michael Donegan's mailing address?
Michael's mailing address filed with the SEC is 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431.
Insiders trading at TherapeuticsMD Inc
Over the last 13 years, insiders at TherapeuticsMD Inc have traded over $21,656,853 worth of TherapeuticsMD Inc stock and bought 721,732 units worth $2,299,099 . The most active insiders traders include Cooper C. Collins, Brian Bernick und Robert G Finizio. On average, TherapeuticsMD Inc executives and independent directors trade stock every 29 days with the average trade being worth of $272,607. The most recent stock trade was executed by John C.K. Iv Milligan on 25 October 2019, trading 72,000 units of TXMD stock currently worth $198,000.
What does TherapeuticsMD Inc do?
therapeuticsmd, inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their health care issues. we create products to address the unique changes and challenges women experience through every stage of their lives. with momentum fueled by the needs of our customers, we combine entrepreneurial spirit and clinical expertise to develop innovative solutions designed to go beyond what is presently available. this includes a variety of therapies in our pipeline, along with prescription prenatal vitamins under the vitamedmd® and bocagreenmd® brands. see our community guidelines: https://www.therapeuticsmd.com/social-media-community-guidelines
What does TherapeuticsMD Inc's logo look like?
Complete history of Mr. Donegan stock trades at TherapeuticsMD und TherapeuticsMD Inc
TherapeuticsMD Inc executives and stock owners
TherapeuticsMD Inc executives and other stock owners filed with the SEC include:
-
John Milligan,
President, Secretary -
Brian Bernick,
Co-Founder -
Robert Finizio,
Chief Executive Officer and Director -
Robert G. Finizio,
Co-Founder & Vice Chair -
Mitchell Krassan,
Chief Strategy and Performance Officer -
John C. K. Milligan IV,
Chief Exec. Officer of VitaCare Prescription Services -
Michael Donegan,
Vice President - Finance -
Tommy Thompson,
Independent Chairman of the Board -
Cooper Collins,
Independent Director -
J. Martin Carroll,
Independent Director -
Angus Russell,
Independent Director -
Jules Musing,
Independent Director -
Dr. Brian A. Bernick,
Co-Founder & Chief Scientific Officer -
Nichol Ochsner,
Vice President, Investor Relations -
Gail Naughton,
Independent Director -
Karen Ling,
Independent Director -
Paul Bisaro,
Independent Director -
Bharat Warrier,
Chief Manufacturing Officer -
Sebastian Mirkin,
Chief Medical Officer -
Dawn Halkuff,
Chief Commercial Officer -
Marlan Walker,
General Counsel -
John Knighton,
Chief Compliance Officer -
Adam Miller,
Chief Information Officer -
James D'Arecca,
Chief Financial Officer -
Julia M. Amadio,
Chief Product Officer -
Mitchell L. Krassan,
Exec. VP and Chief Strategy & Performance Officer -
Chris Gish,
Sr. VP of Sales -
Michael Donegan,
Chief Accounting Officer & VP of Fin. -
James C. D'Arecca,
Chief Financial Officer -
Hugh O'Dowd M.B.A.,
Pres, CEO & Director -
Robert V Jr La Penta,
Director -
Nicholas Segal,
Director -
Jane F Barlow,
Director -
Daniel A Cartwright,
Chief Financial Officer -
Randall S Stanicky,
Director -
Samuel A Greco,
Director